A carregar...
Sorafenib and 2-Deoxyglucose Synergistically Inhibit Proliferation of Both Sorafenib-Sensitive and -Resistant HCC Cells by Inhibiting ATP Production
Hepatocellular carcinoma (HCC) is one of the leading causes of cancer-related deaths globally. Sorafenib is the only first-line systemic drug for advanced HCC, but it has very limited survival benefits because patients treated with sorafenib either suffer from side effects or show disease progressio...
Na minha lista:
| Publicado no: | Gene Expr |
|---|---|
| Main Authors: | , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Cognizant Communication Corporation
2016
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5296238/ https://ncbi.nlm.nih.gov/pubmed/27938509 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3727/105221616X693855 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|